Table 5.

Summary of average Hb by study period (PP population)a

Study PeriodnMean Hb (SD), g/dl
Baseline (weeks −4 to −1)
    twice-monthly C.E.R.A.15411.70 (0.72)
    once-monthly C.E.R.A.15311.58 (0.72)
    epoetin16711.64 (0.70)
Evaluation period (weeks 29 to 36)
    twice-monthly C.E.R.A.15411.70 (1.04)
    once-monthly C.E.R.A.15311.46 (0.99)
    epoetin16711.52 (1.07)
Long-term safety period (weeks 37 to 52)
    twice-monthly C.E.R.A.15211.61 (0.98)
    once-monthly C.E.R.A.14911.51 (0.99)
    epoetin16411.55 (1.07)
  • a PP, per-protocol.